CN110638902A - 番茄提取物在制备降血压药物中的应用及其降血压组合物 - Google Patents
番茄提取物在制备降血压药物中的应用及其降血压组合物 Download PDFInfo
- Publication number
- CN110638902A CN110638902A CN201910942950.9A CN201910942950A CN110638902A CN 110638902 A CN110638902 A CN 110638902A CN 201910942950 A CN201910942950 A CN 201910942950A CN 110638902 A CN110638902 A CN 110638902A
- Authority
- CN
- China
- Prior art keywords
- tomato
- extract
- blood pressure
- ethyl acetate
- petroleum ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000007688 Lycopersicon esculentum Nutrition 0.000 title claims abstract description 94
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 239000000284 extract Substances 0.000 title claims abstract description 31
- 240000003768 Solanum lycopersicum Species 0.000 title claims description 86
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000002220 antihypertensive agent Substances 0.000 title claims description 3
- 230000003276 anti-hypertensive effect Effects 0.000 title description 2
- 229940127088 antihypertensive drug Drugs 0.000 title description 2
- 230000036772 blood pressure Effects 0.000 claims abstract description 57
- 239000002024 ethyl acetate extract Substances 0.000 claims abstract description 31
- 239000003208 petroleum Substances 0.000 claims abstract description 31
- 239000012259 ether extract Substances 0.000 claims abstract description 28
- 230000001603 reducing effect Effects 0.000 claims abstract description 25
- 235000010489 acacia gum Nutrition 0.000 claims abstract description 14
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims abstract description 10
- 229920001353 Dextrin Polymers 0.000 claims description 14
- 239000004375 Dextrin Substances 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 14
- 235000019425 dextrin Nutrition 0.000 claims description 14
- 235000019698 starch Nutrition 0.000 claims description 14
- 239000008107 starch Substances 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000013355 food flavoring agent Nutrition 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 239000000080 wetting agent Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical group O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000007779 soft material Substances 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 229940013618 stevioside Drugs 0.000 claims description 4
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019202 steviosides Nutrition 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000010025 steaming Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 244000019459 Cynara cardunculus Species 0.000 claims description 2
- 235000019106 Cynara scolymus Nutrition 0.000 claims description 2
- 235000016520 artichoke thistle Nutrition 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 235000020879 medical diet Nutrition 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 208000001953 Hypotension Diseases 0.000 claims 3
- 208000021822 hypotensive Diseases 0.000 claims 3
- 230000001077 hypotensive effect Effects 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 2
- 235000013402 health food Nutrition 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 241000227653 Lycopersicon Species 0.000 abstract 8
- 206010020772 Hypertension Diseases 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 9
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 9
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 9
- 239000001751 lycopene Substances 0.000 description 9
- 229960004999 lycopene Drugs 0.000 description 9
- 235000012661 lycopene Nutrition 0.000 description 9
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 9
- 238000013329 compounding Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 229920000084 Gum arabic Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000004531 blood pressure lowering effect Effects 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 3
- 229960001597 nifedipine Drugs 0.000 description 3
- 230000008816 organ damage Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002254 renal artery Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- -1 model group Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提出了一种降血压组合物,由如下重量份组分组成:番茄提取物40‑50份、阿拉伯胶12‑20份,所述番茄提取物为番茄石油醚提取物和番茄乙酸乙酯提取物的组合,其中番茄石油醚提取物:番茄乙酸乙酯提取物的质量比为(10‑40):(12‑35)。本发明研究表明,降血压组合物通过控制其中番茄提取物、阿拉伯胶的重量配比,具有良好的降血压作用,特别是在本发明限定的配比下,其降血压效果更是显著提高,为临床用药提供了新选择。
Description
技术领域
本发明涉及降血压技术领域,具体涉及番茄提取物在制备降血压药物中的应用及其降血压组合物。
背景技术
高血压是最常见的慢性病,也是心脑血管病最主要的危险因素,脑卒中、心肌梗死、心力衰竭及慢性肾脏病是其主要并发症。国内外的实践证明,高血压是可以预防和控制的疾病,降低高血压患者的血压水平,可明显减少脑卒中及心脏病事件,显著改善患者的生存质量,有效降低疾病负担。高血压的危害性与患者的血压水平相关外,还取决于同时存在的其他心血管病危险因素、靶器官损伤以及合并的其他疾病的情况。因此在高血压的定义与分类中,将高血压的诊断标准定在收缩压≥140mmHg和(或)舒张压≥90mmHg,根据血压水平分为正常、正常高值血压和1、2、3级高血压之外,同时还根据危险因素、靶器官损伤和同时合并的其他疾病进行危险分层。高血压患病率随年龄增长而升高;女性在更年期前患病率略低于男性,但在更年期后迅速升高,甚至高于男性;高纬度寒冷地区患病率高于低纬度温暖地区,高海拔地区高于低海拔地区;与饮食习惯有关,盐和饱和脂肪摄入越高,平均血压水平和患病率也越高。我国人群高血压流行有两个比较显著的特点:从南方到北方,高血压患病率呈递增趋势;不同民族之间高血压患病率也有一些差异,生活在北方或高原地区的民族患病率较高,而生活在南方或非高原地区的民族患病率则较低,这种差异可能与地理环境、生活方式等有关,尚未发现各民族之间有明显的遗传背景差异。治疗高血压的主要目的是最大限度地降低心血管发病和死亡的总危险,因此要求医生在治疗高血压的同时,干预患者所有的可逆性心血管危险因素、靶器官损伤和合并存在的临床疾病。对于一般高血压患者降压目标是140/90mmHg以下,对于合并糖尿病或肾病等高危病人,血压应在病人能耐受的情况下酌情降至更低水平。
在成熟番茄中,含有大量的红色显色色素,这种常被称之为番茄红素。过去,人们只将番茄红素红色当做一种天然色素使用,而为对其的药理作用进行深入研究。近年来,越来越多的学者发现,番茄红素其实具有很多的生理活性,是存在于人体血清和其他组织的一种主要的类胡萝卜素。已知的研究表明,番茄红素是一种优秀的抗氧化剂,而且其抗氧化活性明显优于其他类胡萝卜素,同时,番茄红素在调节脂质代谢、增强机体免疫力等方面有明显功效。番茄红素作为一种天然安全无副作用的食品,其生理功能受到了广泛的关注,尤其是其在抗肿瘤方面的活性,成为了现在研究的热点。
番茄红素是一种脂溶性色素,不溶于水,难溶于强极性溶剂如甲醇、乙醇等,可溶于脂肪烃、芳香烃和氯代烃如乙烷、苯、氯仿等有机溶剂。番茄红素在各种溶剂中的溶解度随着温度的上升而增大。
发明内容
本发明提供番茄在制备降血压药物中的应用及其降血压组合物,其目的在于,提供一种番茄提取物的新用途。
本发明提供一种降血压组合物,由如下重量份组分组成:番茄提取物40-50份、阿拉伯胶12-20份,所述番茄提取物为番茄石油醚提取物和番茄乙酸乙酯提取物的组合,其中番茄石油醚提取物:番茄乙酸乙酯提取物的质量比为(10-40):(12-35)。
作为本发明进一步的改进,所述番茄石油醚提取物:番茄乙酸乙酯提取物的质量比为10:12或40:35或10:35或12:40。
本发明进一步保护一种上述降血压组合物在制备降血压药物中的应用。
作为本发明进一步的改进,所述药物制剂为口服制剂、注射制剂或透皮吸收制剂。
本发明进一步保护一种上述降血压组合物在制备降血压保健食品、食品及特殊医疗膳食中的应用。
本发明进一步保护一种降血压颗粒,由以下原料制备而成:番茄提取物、阿拉伯胶、糊精和淀粉的混合物、润湿剂、矫味剂和粘合剂,所述矫味剂为甜菊素,所述粘合剂为水,所述润湿剂为70%的乙醇溶液。
作为本发明进一步的改进,所述番茄提取物为番茄石油醚提取物和番茄乙酸乙酯提取物的组合,其中番茄石油醚提取物:番茄乙酸乙酯提取物的质量比为(10-40):(12-35)。
本发明进一步保护一种上述降血压颗粒的制备方法,包括以下步骤:
S1.朝鲜蓟提取物制备:将番茄洗净、干燥后浸泡在石油醚中,微波加热至35-40℃提取30min后过滤,收集滤液减压除去溶剂后得到番茄石油醚提取物,向滤渣中加入乙酸乙酯,搅拌提取1h后过滤,减压旋蒸除去溶解,得到番茄乙酸乙酯提取物;
S2.干粉制备:按比例将番茄石油醚提取物和番茄乙酸乙酯提取物混合均匀,研细过筛;
S3.颗粒制备:称取干粉和糊精和淀粉的混合物,充分混匀,加入矫味剂,喷以润湿剂和粘合剂,制成软材,筛网制粒,60-75℃常压干燥1h,20目筛整粒,制得降血压颗粒。
作为本发明进一步的改进,所述润湿剂:粘合剂:矫味剂:糊精和淀粉的混合物:干粉的质量比为1:(2-5):(0.5-1:):(35-70):50,所述糊精和淀粉的混合物中糊精和淀粉的质量比为1:2。
作为本发明进一步的改进,步骤S2中筛网目数为100目,步骤 S3中筛网制粒目数为12目。
本发明具有如下有益效果:本发明研究表明,降血压组合物通过控制其中番茄提取物、阿拉伯胶的重量配比,具有良好的降血压作用,特别是在本发明限定的配比下,其降血压效果更是显著提高,为临床用药提供了新选择。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
番茄提取物制备:
S1.番茄石油醚提取物的制备:
将番茄洗净、干燥至含水量低于5%,将100g干番茄切碎,浸泡在石油醚中,固液比1:50g/mL,1000w微波加热至35-40℃,提取30min 后过滤,收集滤液减压除去溶剂后得到番茄石油醚提取物157mg;
S2.番茄乙酸乙酯提取物的制备:
向滤渣中加入乙酸乙酯,固液比为1:30g/mL,500r/min搅拌提取1h后过滤,减压旋蒸除去溶解,得到番茄乙酸乙酯提取物59mg。
实施例2
降血压颗粒的制备:
S1.干粉制备:按番茄石油醚提取物:番茄乙酸乙酯提取物的质量比为10:12,将番茄石油醚提取物和番茄乙酸乙酯提取物混合均匀,研细过100目筛;
S2.颗粒制备:称取50g干粉和35g糊精和淀粉的混合物(糊精和淀粉的质量比为1:2),充分混匀,加入甜菊素0.5g,依次喷以1g 70%的乙醇溶液和2g水,制成软材,12目筛网制粒,60℃常压干燥 1h,20目筛整粒,制得降血压颗粒。
实施例3
降血压颗粒的制备:
S1.干粉制备:按番茄石油醚提取物:番茄乙酸乙酯提取物的质量比为40:35,将番茄石油醚提取物和番茄乙酸乙酯提取物混合均匀,研细过100目筛;
S2.颗粒制备:称取50g干粉和70g糊精和淀粉的混合物(糊精和淀粉的质量比为1:2),充分混匀,加入甜菊素1g,依次喷以1g 70%的乙醇溶液和5g水,制成软材,12目筛网制粒,75℃常压干燥1h, 20目筛整粒,制得降血压颗粒。
测试例1家兔实验
1.1材料与试剂
番茄石油醚提取物、番茄乙酸乙酯提取物,由本发明实施例1提供,番茄由湖南省农科院蔬菜研究中心提供;阿拉伯胶,由郑州格贝斯食品添加剂有限公司提供;硝苯地平,辽宁良性(集团)德峰药业有限公司提供,用生理盐水配制成2.0mg/mL,其他试剂均为国产分析纯。
1.2实验仪器
BL-420E生物信号采集处理系统(成都泰盟科技有限公司)、压力换能器。
1.3实验动物
健康成年家兔120只,体重2~2.5kg,雌雄不限,由南方医科大学动物中心提供(粤医实动准第07号)。
2.实验方法
2.1动物分组与造模:将120只家兔随机分成12组,即番茄提取物高、中、低剂量、模型组、阳性对照组、正常组、番茄石油醚提取物组、番茄乙酸乙酯提取物组、阿拉伯胶组、组合物1组、组合物2组、组合物3组共12组,每组10只。除正常对照组以外的家兔进行双肾动脉狭窄改良术,用银夹同时结扎左右肾动脉主干,导致肾动脉不全狭窄造成肾性高血压模型。喂养4周后,进行实验。
2.2麻醉:家兔称重,耳缘静脉注射1%的戊巴比妥钠(30mg/kg) 麻醉家兔。
2.3手术:将麻醉后家兔固定于兔解剖台上,在颈部正中切开3-7cm 的皮肤切口,分离出一段颈总动脉,远心端用线结扎,近心端用线打一虚结备用,用动脉夹夹住近心端,在紧靠颈总动脉上剪一小口,盛满肝素生理盐水的动脉管插入颈总动脉,立即结扎固定,经压力换能器将血压变化输入生物信号采集处理系统记录和处理,给予160mmHg 左右的前负荷。
2.4给药
放开动脉夹,进行血压测定,待家兔血压稳定后,记录下给药前血压。模型大鼠手术后恢复1周,然后开始灌胃给药,共30天,监测大鼠的生活状况。
正常组(生理盐水,剂量2.5g/kg)、模型组(生理盐水,剂量 2.5g/kg)、阳性对照组(硝苯地平,剂量0.015g/kg),番茄提取物高、中、低剂量组(剂量分别为5.0g/kg、2.5g/kg和1.75g/kg),番茄石油醚提取物组(剂量2.5g/kg)、番茄乙酸乙酯提取物组(剂量2.5g/kg)、阿拉伯胶组(剂量2.5g/kg)、组合物1组(剂量2.5g/kg)、组合物2组(剂量2.5g/kg)和组合物3组(剂量2.5g/kg),模型对照组和正常对照组注射生理盐水,观察血压的变化及恢复时间。
2.5观测指标
平均动脉压(舒张压+1/3脉压差)、血压下降百分率和心率。
2.6统计学处理
3实验结果
注:*:p<0.05,**:p<0.01,与正常组比较,#:p<0.05,##: p<0.01与模型组比较。
模型组与正常组血压比较P<0.01,阳性对照组、番茄提取物高、中、低剂量组、组合物1组、组合物2组、组合物3组与模型组和正常组比较均P<0.05。
由结果可知,给予高血压模型家兔灌胃番茄提取物后,血压立即显著下降,且作用强度呈剂量依赖性,高剂量组有个别家兔血压下降达78%,中剂量番茄提取物与阳性对照药硝苯地平降压效果相当,高剂量组效果更佳,进一步观察,中、高剂量组血压在给药后2小时血压未回升,低剂量组给药后60分钟血压开始回升,到2小时仍未恢复至给药前水平;组合物1组、组合物2组、组合物3组、血压也有显著的下降,其中,组合物3组的降压效果最明显。但从表中看出番茄提取物组以及番茄提取物组合物组的降压效果均比单用番茄石油醚提取物、番茄乙酸乙酯提取物或阿拉伯胶的效果好。
组合物3有番茄提取物和阿拉伯胶复配得到,其降压效果具有协同增效的效果。番茄提取物高、中、低剂量组由番茄石油醚提取物和番茄乙酸乙酯提取物复配得到,两者复配效果增强,明显比单独使用更好。
4结论
将番茄提取物和阿拉伯胶复配或将番茄石油醚提取物和番茄乙酸乙酯提取物复配制备得到的药物具有良好的降血压效果。
与现有技术相比,本发明研究表明,降血压组合物通过控制其中番茄提取物、阿拉伯胶的重量配比,具有良好的降血压作用,特别是在本发明限定的配比下,其降血压效果更是显著提高,为临床用药提供了新选择。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种降血压组合物,其特征在于,由如下重量份组分组成:番茄提取物40-50份、阿拉伯胶12-20份,所述番茄提取物为番茄石油醚提取物和番茄乙酸乙酯提取物的组合,其中番茄石油醚提取物:番茄乙酸乙酯提取物的质量比为(10-40):(12-35)。
2.根据权利要求1所述一种降血压组合物,其特征在于,所述番茄石油醚提取物:番茄乙酸乙酯提取物的质量比为10:12或40:35或10:35或12:40。
3.一种如权利要求1或2所述降血压组合物在制备降血压药物中的应用。
4.根据权利要求3所述应用,其特征在于,所述药物制剂为口服制剂、注射制剂或透皮吸收制剂。
5.一种如权利要求1或2所述降血压组合物在制备降血压保健食品、食品及特殊医疗膳食中的应用。
6.一种降血压颗粒,其特征在于,由以下原料制备而成:番茄提取物、阿拉伯胶、糊精和淀粉的混合物、润湿剂、矫味剂和粘合剂,所述矫味剂为甜菊素,所述粘合剂为水,所述润湿剂为70%的乙醇溶液。
7.根据权利要求6所述一种降血压颗粒,其特征在于,所述番茄提取物为番茄石油醚提取物和番茄乙酸乙酯提取物的组合,其中番茄石油醚提取物:番茄乙酸乙酯提取物的质量比为(10-40):(12-35)。
8.一种如权利要求6或7所述降血压颗粒的制备方法,其特征在于,包括以下步骤:
S1.朝鲜蓟提取物制备:将番茄洗净、干燥后浸泡在石油醚中,微波加热至35-40℃提取30min后过滤,收集滤液减压除去溶剂后得到番茄石油醚提取物,向滤渣中加入乙酸乙酯,搅拌提取1h后过滤,减压旋蒸除去溶解,得到番茄乙酸乙酯提取物;
S2.干粉制备:按比例将番茄石油醚提取物和番茄乙酸乙酯提取物混合均匀,研细过筛;
S3.颗粒制备:称取干粉和糊精和淀粉的混合物,充分混匀,加入矫味剂,喷以润湿剂和粘合剂,制成软材,筛网制粒,60-75℃常压干燥1h,20目筛整粒,制得降血压颗粒。
9.根据权利要求8所述的制备方法,其特征在于,所述润湿剂:粘合剂:矫味剂:糊精和淀粉的混合物:干粉的质量比为1:(2-5):(0.5-1:):(35-70):50,所述糊精和淀粉的混合物中糊精和淀粉的质量比为1:2。
10.根据权利要求8所述的制备方法,其特征在于,步骤S2中筛网目数为100目,步骤S3中筛网制粒目数为12目。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910942950.9A CN110638902A (zh) | 2019-09-30 | 2019-09-30 | 番茄提取物在制备降血压药物中的应用及其降血压组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910942950.9A CN110638902A (zh) | 2019-09-30 | 2019-09-30 | 番茄提取物在制备降血压药物中的应用及其降血压组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110638902A true CN110638902A (zh) | 2020-01-03 |
Family
ID=69012062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910942950.9A Withdrawn CN110638902A (zh) | 2019-09-30 | 2019-09-30 | 番茄提取物在制备降血压药物中的应用及其降血压组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110638902A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101808626A (zh) * | 2007-07-12 | 2010-08-18 | 利库德有限公司 | 治疗高血压的协同联合药物 |
CN104363774A (zh) * | 2012-04-23 | 2015-02-18 | 奥斯陆大学 | 番茄提取物用作抗高血压剂的用途以及制造水溶性无糖番茄提取物的方法 |
CN104688784A (zh) * | 2013-12-10 | 2015-06-10 | 成都百裕科技制药有限公司 | 银杏内酯在制备降血压的药物中的用途 |
CN107106625A (zh) * | 2014-11-25 | 2017-08-29 | 利库德有限公司 | 具有减少量的番茄红素的生物学活性番茄组合物 |
-
2019
- 2019-09-30 CN CN201910942950.9A patent/CN110638902A/zh not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101808626A (zh) * | 2007-07-12 | 2010-08-18 | 利库德有限公司 | 治疗高血压的协同联合药物 |
CN104363774A (zh) * | 2012-04-23 | 2015-02-18 | 奥斯陆大学 | 番茄提取物用作抗高血压剂的用途以及制造水溶性无糖番茄提取物的方法 |
CN104688784A (zh) * | 2013-12-10 | 2015-06-10 | 成都百裕科技制药有限公司 | 银杏内酯在制备降血压的药物中的用途 |
CN107106625A (zh) * | 2014-11-25 | 2017-08-29 | 利库德有限公司 | 具有减少量的番茄红素的生物学活性番茄组合物 |
Non-Patent Citations (4)
Title |
---|
YECHIEL N. ENGELHARD,等: "Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: A double-blind, placebo-controlled pilot study", 《AMERICAN HEART JOURNAL》 * |
刘林林等: "从番茄渣中提取番茄红素的研究现状 ", 《中国果菜》 * |
滕洁等: "番茄红素的提取及其微胶囊化 ", 《冷饮与速冻食品工业》 * |
黄彤: "番茄红素的提取及抗氧化性", 《宜宾学院学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104739921B (zh) | 一种用于缓解视疲劳的组方含片及其制备方法 | |
JP2004075638A (ja) | 血糖上昇抑制且つ血圧上昇抑制作用を有する機能性素材 | |
CN107080250A (zh) | 一种辅助降血糖的组合物、饮料及其制备方法 | |
CN106344648A (zh) | 一种百里香属植物、提取物及其应用 | |
CN107581543A (zh) | 一种降血糖复合冲剂 | |
CN109925310B (zh) | 含有治疗有效量银杏内酯的降血压药物 | |
CN104800608B (zh) | 一种具有降血压功效的中草药组合物及其应用 | |
JP2000191542A (ja) | 骨粗鬆症予防、治療剤 | |
CN118490802A (zh) | 一种用于改善运动心肌损伤的组合物 | |
KR101359806B1 (ko) | 혈당강하에 효능이 있는 돼지감자 및 꾸지뽕잎의 복합추출물 및 이를 이용한 건강기능식품 조성물 | |
CN110638902A (zh) | 番茄提取物在制备降血压药物中的应用及其降血压组合物 | |
CN1997358A (zh) | 贝壳杉烷类化合物在制备药物中的应用 | |
CN112370496A (zh) | 枸杞叶有效成分在制备预防或治疗肝纤维化药物中的应用 | |
CN101336965B (zh) | 一种用于改善糖耐量、降低血糖的中成药及其制备方法 | |
KR100964603B1 (ko) | 주목과 뽕나무 추출물을 이용한 당뇨 치료용 약학 조성물 및 이의 제조 방법 | |
KR101467407B1 (ko) | 황칠나무 추출물을 유효성분으로 함유하는 혈당조절용 식품 조성물 | |
CN108434166B (zh) | 一种血塞通药物组合物及其制备方法、制剂与应用 | |
JP2021159063A (ja) | コンニャク機能性食品及びその製造方法 | |
CN100581552C (zh) | 用于治疗心脑血管疾病的药物——复方葛根素 | |
CN107136269B (zh) | 一种青钱柳苦瓜降糖茶及其制备方法 | |
KR20200132261A (ko) | 싸리 추출물을 포함하는 근위축 예방 및 치료용 조성물 | |
CN113116868B (zh) | 四氢次大麻酚在肺动脉高压的预防和/或治疗中的应用 | |
CN111759878A (zh) | 一种降血糖的中药组合物及其制备方法 | |
CN104688755B (zh) | 栀子苷的医药用途 | |
CN110638853A (zh) | 朝鲜蓟叶提取物在制备降血压的药物中的用途及其组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200103 |
|
WW01 | Invention patent application withdrawn after publication |